Arch Biopartners Enters Agreement to Develop Prototype Diagnostic Imaging Agents for Brain Tumor Stem Cells

Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) and its
subsidiary Arch Cancer Therapeutics ("ACT") today announced ACT has entered into
an Agreement for Research Services (the "Agreement") with the National Research
Council of Canada (NRC). Under the agreement, the NRC will combine ACT's brain
tumor initiating cell (BTIC)-targeting peptide technology with paramagnetic
nanoparticles to develop prototype BTIC diagnostic imaging agents for use in
magnetic resonance imaging ("MRI").


BTICs are a cancer stem cell population that represent a significant disease
reservoir believed to play an important role in the formation and recurrence of
malignant glioma in humans. BTICs are not detected by current medical diagnostic
imaging technologies.


Paramagnetic nanoparticles are small injectable particles used for molecular
imaging and can be visualized by MRI. It is anticipated the combination of ACT's
BTIC targeting peptides and paramagnetic nanoparticles will for the first time
make BTICs visible.


It is expected that this development contract, including animal in vivo testing,
will be completed within nine months, and if successful, will further validate
ACT's BTIC-targeting technology as a potential diagnostic tool for human
malignant glioma.


About Arch Cancer Therapeutics 

ACT is an Alberta corporation wholly owned by Arch Biopartners. ACT's objective
is to develop non-invasive diagnostic and therapeutic molecules for brain cancer
utilizing new and innovative approaches. 


Despite intensive research over the past 30 years, clinical outcomes for
patients with malignant glioma have not changed substantially with average
survival rates remaining at a dismal 12-15 months. ACT's proprietary molecules
are specialized peptides that identify and target brain tumor initiating cells
("BTIC") and invasive brain cancer cells, two disease reservoirs that are not
normally seen using current state of the art diagnostic imaging techniques. 


About Arch Biopartners 

Arch Biopartners is a portfolio based biotechnology company established to
developing early stage proprietary technology for sale to pharmaceutical and
industrial companies.


The Company's website address is: www.archbiopartners.com.

For more information on the Company, please consult the other public documents
filed on SEDAR at www.sedar.com. 


Forward-Looking Statements 

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.